Source: Annual Congress 2011 - Diagnosis and treatment of inflammatory respiratory diseases
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
L. Jurgauskiene, E. Danila, R. Malickaite (Vilnius, Lithuania). Is it useful CD4+CD103+/CD4+ ratio for the diagnosis of lung sarcoidosis?. Eur Respir J 2011; 38: Suppl. 55, 4083

Member's Comments

No comment yet.

Related content which might interest you: Pulmonary rehabilitation in patients with interstitial lung disease – An useful therapeutic option? Source: Annual Congress 2011 - Pulmonary rehabilitation: looking at alternative approaches and alternative populations beyond COPD Year: 2011 Is bronchoscopic lung biopsy helpful in the management of patients with diffuse lung disease? Source: Eur Respir J 2007; 29: 1064 Year: 2007 Is the S-ECP/Eo ratio of any benefit for diferential diagnosis of early childhood bronchial asthma? Source: Eur Respir J 2004; 24: Suppl. 48, 612s Year: 2004 Case for diagnosis Source: Annual Congress 2005 - Paediatric Clinical Grand Round: an interactive session Year: 2005 Is FEV1/FEV6 ratio a reliable  tool in COPD diagnosis ? Source: Virtual Congress 2021 – Biomarkers to phenotype COPD: prediction of exacerbations Year: 2021 How to achieve the higher diagnostic yield using EBUS-TBNA method to confirm sarcoidosis? Source: International Congress 2016 – EBUS and transthoracic ultrasound Year: 2016 Diffuse parenchymal lung disease: a practical overview Is a lung biopsy necessary for management? Source: Breathe 2008; 4: 233-239 Year: 2008 HRCT in the diagnosis of diffuse lung disease - overlap issues Source: Research Seminar 2010 - Novel insights in pulmonary fibrogenesis: from bench to bedside Research Seminar Year: 2010 Does surgical lung biopsy change the diagnosis and treatment in interstitial lung diseases? Source: Annual Congress 2010 - Different patterns of diffuse parenchymal lung disease Year: 2010 Transbronchial lung biopsy (TLB): still a valid tool to lung disease diagnosis? Source: Eur Respir J 2006; 28: Suppl. 50, 516s Year: 2006 Comparison of the diagnostic yield of bronchoscopy in the investigation of suspected tuberculosis in patients with and without parenchymal changes Source: Annual Congress 2013 –Tuberculosis: epidemiology and public health management III Year: 2013 Cardiac sarcoidosis: screening, diagnosis and treatment Source: International Congress 2019 – State of the art session: Interstitial lung diseases Year: 2019 Is virtual bronchoscopy (VB) useful in diagnosing of peripheral lung cancer? Source: Eur Respir J 2007; 30: Suppl. 51, 667s Year: 2007 Neutrophil-to-lymphocyte ratio in IPF patients: a novel prognostic biomarker? Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis Year: 2020 Radiological diagnosis of interstitial lung disease: is it all about pattern recognition? Source: Eur Respir J, 52 (2) 1801321; 10.1183/13993003.01321-2018 Year: 2018 Periostin and TSLP: New markers useful in diagnosis of obstructive lung disease Source: International Congress 2015 – Modulating the immune system in COPD and asthma Year: 2015 Role of lung biopsies in the diagnosis of interstitial lung diseases in a clinical real-life setting Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases Year: 2021 Delay in diagnosis of interstitial lung diseases (ILD) Source: Annual Congress 2007 - Clinical aspects of interstitial lung disease Year: 2007 Comparative role of serum cathepsin S concentrations for differential diagnosis of sarcoidosis from other lung diseases Source: International Congress 2015 – Sarcoidosis: pathogenesis Year: 2015